Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
denosumab osteoclast differentiation factor NA Successful target TTD , DGIDB Hip Fractures[MeSHID:D006620]
Neoplasms[MeSHID:D009369]
Bone structure of spine[MeSHID:D013131]
Fracture[MeSHID:D050723]
Malignant neoplasm of prostate[MeSHID:D011471]
Neoplasm Metastasis[MeSHID:D009362]
Bone Density[MeSHID:D015519]
Malignant neoplasm of breast[MeSHID:D001943]
Bone Tissue[MeSHID:D001842]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Rheumatoid Arthritis[MeSHID:D001172]		 71.61 approved unknown
denosumab tumor necrosis factor ligand superfamily member 11 biotech NA drugbank , DGIDB Hip Fractures[MeSHID:D006620]
Neoplasms[MeSHID:D009369]
Bone structure of spine[MeSHID:D013131]
Fracture[MeSHID:D050723]
Malignant neoplasm of prostate[MeSHID:D011471]
Neoplasm Metastasis[MeSHID:D009362]
Bone Density[MeSHID:D015519]
Malignant neoplasm of breast[MeSHID:D001943]
Bone Tissue[MeSHID:D001842]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Rheumatoid Arthritis[MeSHID:D001172]		 71.61 approved antibody,inhibitor
denosumab tumor necrosis factor ligand superfamily member 11 biotech NA drugbank , DGIDB Hip Fractures[MeSHID:D006620]
Neoplasms[MeSHID:D009369]
Bone structure of spine[MeSHID:D013131]
Fracture[MeSHID:D050723]
Malignant neoplasm of prostate[MeSHID:D011471]
Neoplasm Metastasis[MeSHID:D009362]
Bone Density[MeSHID:D015519]
Malignant neoplasm of breast[MeSHID:D001943]
Bone Tissue[MeSHID:D001842]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Rheumatoid Arthritis[MeSHID:D001172]		 71.61 approved antibody
denosumab osteoclast differentiation factor NA Successful target TTD , DGIDB Hip Fractures[MeSHID:D006620]
Neoplasms[MeSHID:D009369]
Bone structure of spine[MeSHID:D013131]
Fracture[MeSHID:D050723]
Malignant neoplasm of prostate[MeSHID:D011471]
Neoplasm Metastasis[MeSHID:D009362]
Bone Density[MeSHID:D015519]
Malignant neoplasm of breast[MeSHID:D001943]
Bone Tissue[MeSHID:D001842]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Rheumatoid Arthritis[MeSHID:D001172]		 71.61 approved antibody
denosumab osteoclast differentiation factor NA Successful target TTD , DGIDB Hip Fractures[MeSHID:D006620]
Neoplasms[MeSHID:D009369]
Bone structure of spine[MeSHID:D013131]
Fracture[MeSHID:D050723]
Malignant neoplasm of prostate[MeSHID:D011471]
Neoplasm Metastasis[MeSHID:D009362]
Bone Density[MeSHID:D015519]
Malignant neoplasm of breast[MeSHID:D001943]
Bone Tissue[MeSHID:D001842]
Osteoporosis[MeSHID:D010024]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Osteoporosis
Postmenopausal[MeSHID:D015663]
Rheumatoid Arthritis[MeSHID:D001172]		 71.61 approved inhibitor
click here to return to the previous page